RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

APU_85, >> CX1739 for RD trial instead of building off the CX717? <<



CX-717 had the 'artifact' problem, which is what derailed its development previously. CX-1739 is a newer generation Ampakine, approx 3 times more potent than CX-717, so its efficacy in RD should be even better than CX-717's. Respiratory trials can be somewhat tricky to run though, as Cortex found out previously, but barring technical glitches, the trial should have a very good chance of success based on the previously demonstrated efficacy of CX-717 in RD.

The comp of matter patent for CX-1739 runs to 2028 (there are also broad use patents for the Respiratory indications), and the compound has already proven itself in the earlier Sleep Apnea Phase 2a trial, which showed such phenomenal efficacy in the Central type Sleep Apnea patients. Efficacy in that cohort (Central type SA) was nothing short of amazing, albeit in a small group of patients.

These Respiratory trials will be extremely interesting.